138 related articles for article (PubMed ID: 20380330)
1. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
Schuman SI; Lambrou N; Robson K; Glück S; Myriounis N; Pearson JM; Lucci JA
J Support Oncol; 2009; 7(6):225-8. PubMed ID: 20380330
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
3. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
[TBL] [Abstract][Full Text] [Related]
8. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
9. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Siena S; Piccart MJ; Holmes FA; Glaspy J; Hackett J; Renwick JJ
Oncol Rep; 2003; 10(3):715-24. PubMed ID: 12684649
[TBL] [Abstract][Full Text] [Related]
10. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
13. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
15. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
16. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim for chemotherapy-induced neutropenia.
Bedell C
Clin J Oncol Nurs; 2003; 7(1):55-6, 63-4. PubMed ID: 12629935
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
Romieu G; Clemens M; Mahlberg R; Fargeot P; Constenla M; Schütte M; Easton V; Skacel T; Bacon P; Brugger W
Crit Rev Oncol Hematol; 2007 Oct; 64(1):64-72. PubMed ID: 17317205
[TBL] [Abstract][Full Text] [Related]
20. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]